Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 5/20 | 0.43 |
| ▸ | SSTR4 | P31391 | 3/20 | 0.42 |
| ▸ | SSTR1 | P30872 | 2/20 | 0.41 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.40 |
| ▸ | RXRA | P19793 | 1/20 | 0.40 |
| ▸ | RXRB | P28702 | 1/20 | 0.40 |
| ▸ | RXRG | P48443 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.38 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.37 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.37 |
| ▸ | CTSS | P25774 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 1/20 | 0.36 |
| ▸ | MRGPRX1 | Q96LB2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16252771 | 0.82 | SSTR4 (0.46) | ARSSTR4SSTR1RXRARXRB | |
| SCHEMBL31413934 | 0.80 | AAK1 (0.42) | ARSSTR4CYP3A4AAK1MRGPRX4 | |
| SCHEMBL3168510 | 0.80 | AAK1 (0.42) | ARSSTR4CYP3A4AAK1MRGPRX4 | |
| SCHEMBL28060228 | 0.76 | RXRA (0.50) | SSTR4SSTR1RXRARXRBRXRG | |
| SCHEMBL3428539 | 0.76 | KMT2A (0.41) | SSTR4RXRARXRBRXRGCYP3A4 | |
| SCHEMBL14499044 | 0.76 | MEN1 (0.45) | SSTR4SSTR1RXRARXRBRXRG | |
| SCHEMBL10031201 | 0.76 | RIPK1 (0.44) | ARSGMS2 | |
| SCHEMBL14242284 | 0.76 | SSTR4 (0.46) | ARSSTR4SSTR1RXRARXRB | |
| SCHEMBL14227158 | 0.76 | SSTR4 (0.46) | ARSSTR4SSTR1RXRARXRB | |
| SCHEMBL31391964 | 0.74 | RXRA (0.45) | ARRXRARXRBRXRGMRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7705044-B2 | Benzamidoacetonitriles and their use as antiparasitics | NOVARTIS AG (CH) | 2010-04-27 | — | — | US | disclosed |
| EP-1758849-A1 | AMINOACETONITRILE DERIVATIVES AND THEIR USE FOR CONTROLLING PARASITES ON WARM-BLOODED ANIMALS | Novartis AG (CH) | 2007-03-07 | — | — | EP | disclosed |
| EP-1390344-B1 | BENZAMIDOACETONITRILE DERIVATIVES AND THEIR USE AS ANTIPARASITICS | NOVARTIS AG (CH) | 2006-12-27 | — | — | EP | disclosed |
| WO-2005121075-A1 | AMINOACETONITRILE DERIVATIVES AND THEIR USE FOR CONTROLLING PARASITES ON WARM-BLOODED ANIMALS | NOVARTIS AG (CH) | 2005-12-22 | — | — | WO | disclosed |
| US-20040220055-A1 | Benzamidoacetonitriles and their use as antiparastics | NOVARTIS AG (CH) | 2004-11-04 | — | — | US | disclosed |
| EP-1390344-A2 | ORGANIC COMPOUNDS | Novartis AG (CH) | 2004-02-25 | — | — | EP | disclosed |
| WO-2002092552-A2 | BENZAMIDOACETONITRILES AND THEIR USE AS ANTIPARASITICS | NOVARTIS AG (CH) | 2002-11-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220055-A1 | Benzamidoacetonitriles and their use as antiparastics | ACHE, BPNT1, NAT1 | AR 3810/4885SSTR4 4422/4885SSTR1 2728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.